AVTR vs DHR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AVTR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AVTR and DHR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AVTR and DHR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Avantor, Inc. is a global provider of high-purity materials, consumables, equipment, and specialized services used across biopharma, healthcare, education, government, and advanced technology markets. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company sells everything from high-purity chemicals and reagents, lab supplies, and customized excipients to single-use assemblies, chromatography resins, and fluid handling systems. It reorganized around two reporting segments (Laboratory Solutions and a Bioscience and Medtech Products grouping), and a large share of its revenue is recurring consumables that customers reorder repeatedly, which gives the model a razor-and-blade quality tied to laboratory activity and biologic manufacturing volumes.

Full AVTR guide

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AVTR drivers: Revival transformation program; Recurring consumables and bioprocessing exposure.
• DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Avantor's revenue was only flat in Q2 2026 and consensus still implies a roughly 5.5% year-over-year decline for Q3, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. For DHR, valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 41x on GAAP earnings with a forward P/E near 25x as of October 16, 2026), leaving little room for disappointment.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AVTR if you believe its drivers more; DHR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AVTR and DHR guides.

AVTR. As of October 2026 Avantor trades at about 18.5x forward earnings and about 1.7x sales, a valuation that has re-rated sharply since the summer as two straight beats eased fears about the turnaround. It still sits at a discount to larger, higher-margin tools peers because of its slower growth and higher leverage. Figures are approximate and reference reported results through Q2 2026 and consensus estimates as of October 16, 2026.

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, and growth picked up to about 5.5% in the second quarter of 2026. After a 29% three-month rally, the stock trades near 25x forward earnings and about 23x EV/EBITDA, the upper part of its usual premium range, with consensus EPS of about $8.51 for 2026 and $9.30 for 2027. The 22 analysts tracked by Yahoo Finance hold a strong buy consensus with a mean target near $244, close to the current price; figures are approximate and as of October 16, 2026.

Headline figures (approximate, October 2026): AVTR shows revenue (ttm) ~$6.56B, q2 2026 revenue ~$1.69B (flat YoY, ~5% above estimates), gross / operating margin ~32% / ~7%, net income (ttm, gaap) ~-$578M (Q3 2025 write-down); DHR shows revenue (ttm) ~$25.1B; Q2 2026 ~$6.26B (+5.5%), q2 2026 adj. eps $1.94 vs ~$1.84 estimate, margins (ttm) ~58.8% gross, ~19.8% operating, ~16.0% net, net income (ttm) ~$3.99B (GAAP EPS ~$5.61).

AVTR and DHR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AVTR and DHR exposure against your real portfolio. It is not an investment adviser.